Neurodegeneration: From Mechanisms to Precision Diagnosis and Therapies (M1)
April 11-14, 2027
| Whistler Conference Centre, Whistler, BC, Canada
Bruce Miller, Ana Maria Cuervo and Brandy Matthews
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
| 8:00–9:30 AM |
Welcome and Keynote Session (Joint) |
|
| |
Alfred Njamnshi †, University of Yaoundé
Infectious Disease Life-Time Impact on Cognition |
|
| |
Daniel S. Reich †, NINDS, National Institutes of Health
Combining Advanced Imaging and Biological Insights for Better Disease Progression |
|
| 9:30–9:50 AM |
Coffee Break |
|
| 9:30–11:15 AM |
Molecular Insights into the Interplay between Neurodegeneration and Neuroinflammation (Joint) |
|
| |
Li Gan †, Weill Cornell Medicine
Converging Molecular Mechanisms of Neurodegeneration |
|
| |
Mariko Bennett †, University of Pennsylvania
The Potential of Microglia-Based Therapies in Neurodegeneration |
|
| |
David M Holtzman †, Washington University
Innate and Adaptive Immune System in tau-Mediated Neurodegeneration |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 11:15–12:15 PM |
Panel Discussion 1: New Modalities in Neuro-Diagnosis and Therapeutics (Joint) |
|
| 12:15–1:00 PM |
Poster Setup |
|
| 12:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: AI/Machine Learning - from basic Discovery to Clinical Diagnosis |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Cellular Mechanisms of Defense against Proteotoxicity in the Central Nervous System |
|
| |
Carmela Sidrauski †, Calico Life Sciences LLC
The Integrated Stress Response in Neurodegeneration |
|
| |
Ana Maria Cuervo, Albert Einstein College of Medicine
Selective Autophagy Malfunction in Neurodegeneration |
|
| |
Lidia Wróbel †, International Institute of Molecular and Cell Biology
Nuclear Protein Quality Control in Neurodegenerative Diseases |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Genetic and Non-Genetic Disease Modifiers |
|
| |
Daniel H. Geschwind †, University of California, Los Angeles
Gene Networks in Neurodegeneration |
|
| |
Sarah Marzi †, King's College London
Epigenetic Regulation of Neurodegenerative Diseases |
|
| |
Fen-Biao Gao †, University of Massachusetts Medical School
Pathogenic Pathways in ALS |
|
| |
Rosa Rademakers †, VIB-UAntwerp Center for Molecular Neurology
Advances in frontotemporal Dementia Genetics |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Cognitive Decline Beyond AD: Non AD Dementias |
|
| |
Bruce Miller, University of California, San Francisco
Non-AD Dementias |
|
| |
Fanny Elahi †, Icahn School of Medicine at Mount Sinai
Vascular Dementia |
|
| |
Pedro Pinheiro-Chagas †, University of California, San Francisco
AI Advances in the Clinic |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, April 14, 2027
| 8:00–11:00 AM |
Translating Innovation: Clinical Advances in Neurodegeneration and Neuroimmunology (Joint) |
|
| |
Henrik Zetterberg †, University of Gothenburg
Biomarkers in Neurodegeneration and Neuroinflammation |
|
| |
Manuela Polydoro †, Muna Therapeutics
Translational Biomarkers in Drug Discovery |
|
| |
James Keaney †, F. Hoffmann-La Roche
Omics Approaches to Drug Discovery in Neurodegeneration and Neuroinflammation |
|
| |
Joy Yu Zuchero †, Denali Therapeutics Inc
Challenges for CNS Drug-Discovery |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Emerging Therapeutics for Neurodegenerative Disorders |
|
| |
Brandy Matthews, Eli Lilly and Company
Efficacy of Clinical Trials for Amyloid Lowering |
|
| |
Olga Uspenskaya-Cadoz †, VectorY Therapeutics
Investigational Therapeutics for FTD |
|
| |
Ivana Rubino †, Biogen
Challenges for Clinical Translation across Neuroinflammation and Neurodegeneration |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
